Safety and efficacy of Lippia multiflora in the management of stage I hypertension: outcomes of a randomised controlled trial

IF 2.2 4区医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE

Journal of Herbal Medicine Pub Date : 2024-09-25 DOI:10.1016/j.hermed.2024.100947

Ama Kyeraa Thomford , Kwesi Prah Thomford , Andrews Ebo Tetteh , Rosemary Sorkpor , Joseph Yorke

{"title":"Safety and efficacy of Lippia multiflora in the management of stage I hypertension: outcomes of a randomised controlled trial","authors":"Ama Kyeraa Thomford , Kwesi Prah Thomford , Andrews Ebo Tetteh , Rosemary Sorkpor , Joseph Yorke","doi":"10.1016/j.hermed.2024.100947","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Hypertension is a growing public health problem in the developing world. The chronic nature of the disease has been a driver for the use of traditional medicines. Clinical validation of such products for their safety and efficacy is thus of public health importance. We report on the clinical safety and effectiveness of a <em>Lippia multiflora-</em>based herbal antihypertensive <em>(LMT-19)</em>.</div></div><div><h3>Methods</h3><div>A randomised controlled study was conducted among 80 volunteers clinically diagnosed, per the WHO criteria, with stage I hypertension. Participants received either an aqueous infusion of <em>LMT-19</em> plus a standard lifestyle and dietary recommendation based on a Dietary Approaches to Stop Hypertension (DASH) diet or the lifestyle and dietary recommendation alone.</div></div><div><h3>Results</h3><div>The use of <em>LMT-19</em> resulted in a significant decline of blood pressure over a 60-day period. Diastolic blood pressure in the <em>LMT-19</em> group was found to be significantly lower compared to the control (<em>mean diff</em>: 8.25 (±1.50); <em>P</em> ≤ 0.001). Systolic blood pressure was also significantly better compared to the control group (<em>mean diff:</em> 12.70 ± 2.02; <em>P</em> ≤ 0.001). The product was also well tolerated as no adverse drug reactions were also recorded during the study.</div></div><div><h3>Conclusion</h3><div>These outcomes suggest <em>LMT-19</em> as a potential alternative remedy for management of stage I hypertension.</div></div><div><h3>Clinical trial registration</h3><div>Pan-African Clinical Trial Registry, PACTR202107733803271.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":"48 ","pages":"Article 100947"},"PeriodicalIF":2.2000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Herbal Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2210803324001040","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Hypertension is a growing public health problem in the developing world. The chronic nature of the disease has been a driver for the use of traditional medicines. Clinical validation of such products for their safety and efficacy is thus of public health importance. We report on the clinical safety and effectiveness of a Lippia multiflora-based herbal antihypertensive (LMT-19).

Methods

A randomised controlled study was conducted among 80 volunteers clinically diagnosed, per the WHO criteria, with stage I hypertension. Participants received either an aqueous infusion of LMT-19 plus a standard lifestyle and dietary recommendation based on a Dietary Approaches to Stop Hypertension (DASH) diet or the lifestyle and dietary recommendation alone.

Results

The use of LMT-19 resulted in a significant decline of blood pressure over a 60-day period. Diastolic blood pressure in the LMT-19 group was found to be significantly lower compared to the control (mean diff: 8.25 (±1.50); P ≤ 0.001). Systolic blood pressure was also significantly better compared to the control group (mean diff: 12.70 ± 2.02; P ≤ 0.001). The product was also well tolerated as no adverse drug reactions were also recorded during the study.

Conclusion

These outcomes suggest LMT-19 as a potential alternative remedy for management of stage I hypertension.

Clinical trial registration

Pan-African Clinical Trial Registry, PACTR202107733803271.

查看原文本刊更多论文

多花菩提子治疗 I 期高血压的安全性和疗效：随机对照试验的结果

导言高血压是发展中国家日益严重的公共卫生问题。这种疾病的慢性性质推动了传统药物的使用。因此，对此类产品的安全性和有效性进行临床验证具有重要的公共卫生意义。我们报告了以多花菩提草为基础的草药降压药（LMT-19）的临床安全性和有效性。方法在 80 名根据世界卫生组织标准临床诊断为 I 期高血压的志愿者中进行了随机对照研究。参加者接受了 LMT-19 的水溶液注射，同时还接受了基于饮食疗法（DASH）的标准生活方式和饮食建议，或者只接受了生活方式和饮食建议。与对照组相比，LMT-19 组的舒张压明显降低（平均差值为 8.25（±1.50））：8.25 (±1.50); P ≤ 0.001).收缩压也明显优于对照组（平均差：12.70 ± 2.02；P ≤ 0.001）。结论这些结果表明，LMT-19 是治疗 I 期高血压的潜在替代药物。临床试验注册泛非临床试验注册中心，PACTR202107733803271。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Herbal Medicine INTEGRATIVE & COMPLEMENTARY MEDICINE-

CiteScore

3.90

自引率

0.00%

发文量

期刊介绍： The Journal of Herbal Medicine, the official journal of the National Institute of Medical Herbalists, is a peer reviewed journal which aims to serve its readers as an authoritative resource on the profession and practice of herbal medicine. The content areas of the journal reflect the interests of Medical Herbalists and other health professionals interested in the clinical and professional application of botanical medicines. The objective is to strengthen the research and educational base of herbal medicine with research papers in the form of case studies, original research articles and reviews, monographs, clinical trials and relevant in vitro studies. It also publishes policy statements, opinion pieces, book reviews, conference proceedings and profession related information such as pharmacovigilance reports providing an information source for not only the Herbal Practitioner but any Health professional with an interest in phytotherapy.